University of Pennsylvania 
Welcome,         Profile    Billing    Logout  
 27 Products   14 Diseases   27 Products   39 Trials   6077 News 


«12...55565758596061626364656667»
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Trial completion, Trial primary completion date:  CART-19 for Multiple Myeloma (clinicaltrials.gov) -  Oct 5, 2015   
    P1,  N=13, Completed, 
    Trial primary completion date: Jul 2015 --> Jan 2018 Recruiting --> Completed | Trial primary completion date: May 2016 --> Sep 2015
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Trial initiation date:  Study of Efficacy and Safety of CTL019 in Adult ALL Patients (clinicaltrials.gov) -  Oct 1, 2015   
    P2,  N=67, Not yet recruiting, 
    Trial primary completion date: Jul 2015 --> Jul 2016 Initiation date: Jun 2014 --> Jun 2016
  • ||||||||||  MTV273 / Novartis
    New trial:  CART-BCMA Cells for Multiple Myeloma (clinicaltrials.gov) -  Sep 10, 2015   
    P0,  N=30, Recruiting, 
  • ||||||||||  autologous redirected RNA meso-CIR T cells / University of Pennsylvania
    Trial completion, Trial primary completion date:  Autologous Redirected RNA Meso-CIR T Cells (clinicaltrials.gov) -  Aug 12, 2015   
    P1,  N=18, Completed, 
    N=14 --> 110 | Trial primary completion date: Oct 2013 --> Jul 2015 Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Jul 2015
  • ||||||||||  Ad-RTS-hIL-12 / Alaunos Therap, veledimex (INXN-1001) / University of Pennsylvania
    Enrollment open, IO biomarker, Metastases:  A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer (clinicaltrials.gov) -  Aug 7, 2015   
    P1/2,  N=40, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Enrollment open, Trial primary completion date:  Dose Optimization Trial of CD19 Redirected Autologous T Cells (clinicaltrials.gov) -  Jul 14, 2015   
    P2,  N=34, Recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2017 --> Jun 2018 Completed --> Recruiting | Trial primary completion date: Jul 2014 --> Jul 2016
  • ||||||||||  Lentiviral-based CART-meso gene therapy / University of Pennsylvania
    Enrollment change, Gene therapy:  CART-meso Long-term Follow-up (clinicaltrials.gov) -  Jun 22, 2015   
    P=N/A,  N=50, Recruiting, 
    Completed --> Recruiting | Trial primary completion date: Jul 2014 --> Jul 2016 N=100 --> 50
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences
    Trial primary completion date, Combination therapy:  Birinapant With 5-azacitidine in MDS Subjects Who Are Na (clinicaltrials.gov) -  Jun 18, 2015   
    P1/2,  N=45, Active, not recruiting, 
    N=100 --> 50 Trial primary completion date: May 2015 --> Aug 2015
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Trial primary completion date:  JULIET: Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (clinicaltrials.gov) -  Jun 14, 2015   
    P2,  N=100, Not yet recruiting, 
    Trial primary completion date: May 2015 --> Aug 2015 Trial primary completion date: Jun 2021 --> Sep 2021
  • ||||||||||  Lentiviral-based CART-meso gene therapy / University of Pennsylvania
    Enrollment open, Gene therapy:  CART-meso Long-term Follow-up (clinicaltrials.gov) -  Jun 8, 2015   
    P=N/A,  N=100, Recruiting, 
    Trial primary completion date: Jun 2021 --> Sep 2021 Not yet recruiting --> Recruiting
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Trial completion, Trial primary completion date:  Allo CART-19 Protocol (clinicaltrials.gov) -  Jun 8, 2015   
    P1,  N=10, Completed, 
    Active, not recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences, conatumumab (AMG 655) / Amgen
    Enrollment closed, Trial primary completion date:  Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (clinicaltrials.gov) -  Jun 1, 2015   
    P1,  N=40, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> May 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Aug 2015
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences
    Enrollment closed:  Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B (clinicaltrials.gov) -  May 8, 2015   
    P1,  N=48, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Aug 2015 Recruiting --> Active, not recruiting
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Enrollment open:  CD19 Redirected Autologous T Cells for Hodgkin Lymphoma (clinicaltrials.gov) -  Apr 7, 2015   
    P0,  N=16, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting
  • ||||||||||  Lentiviral-based CART-meso gene therapy / University of Pennsylvania
    Gene therapy:  CART-meso Long-term Follow-up (clinicaltrials.gov) -  Mar 17, 2015   
    P=N/A,  N=100, Not yet recruiting, 
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences
    Trial primary completion date:  Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (clinicaltrials.gov) -  Feb 3, 2015   
    P2,  N=11, Completed, 
    Initiation date: Jun 2014 --> Mar 2015 Trial primary completion date: Apr 2014 --> Dec 2013
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences
    Enrollment closed, Trial primary completion date, Combination therapy:  Birinapant With 5-azacitidine in MDS Subjects Who Are Na (clinicaltrials.gov) -  Jan 22, 2015   
    P1/2,  N=45, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> May 2015
  • ||||||||||  autologous redirected RNA meso-CIR T cells / University of Pennsylvania
    Enrollment closed, Trial primary completion date:  Autologous Redirected RNA Meso-CIR T Cells (clinicaltrials.gov) -  Oct 17, 2014   
    P1,  N=6, Active, not recruiting, 
    Not yet recruiting --> Recruiting Completed --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Oct 2015
  • ||||||||||  birinapant (IGM-9427) / IGM Biosciences, conatumumab (AMG 655) / Amgen
    Trial primary completion date:  Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (clinicaltrials.gov) -  Oct 15, 2014   
    P1,  N=40, Recruiting, 
    Completed --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Oct 2015 Trial primary completion date: Sep 2014 --> Apr 2015
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Trial primary completion date:  Allo CART-19 Protocol (clinicaltrials.gov) -  Oct 15, 2014   
    P1,  N=10, Active, not recruiting, 
    Trial primary completion date: Sep 2014 --> Apr 2015 Trial primary completion date: Sep 2013 --> Sep 2015
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Enrollment open:  Study of Efficacy and Safety of CTL019 in Adult ALL Patients (clinicaltrials.gov) -  Oct 15, 2014   
    P2,  N=67, Recruiting, 
    Trial primary completion date: Sep 2013 --> Sep 2015 Active, not recruiting --> Recruiting
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis
    Trial completion, Trial primary completion date:  Dose Optimization Trial of CD19 Redirected Autologous T Cells (clinicaltrials.gov) -  Oct 15, 2014   
    P2,  N=34, Completed, 
    Active, not recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2014
  • ||||||||||  autologous redirected RNA meso-CIR T cells / University of Pennsylvania
    Trial completion, Trial primary completion date:  Autologous Redirected RNA Meso-CIR T Cells (clinicaltrials.gov) -  Oct 10, 2014   
    P1,  N=6, Completed, 
    Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2014 Recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2014